Celgene Corporation

Agios Pharmaceuticals, Inc.

Michael D Amatangelo

Anjan Thakurta

Chad Bjorklund

Rajesh Chopra

Anita Gandhi

Sung Eun Choe

Bin Wu

Xiankang Hong

Xiaolan Hu

Mariana Cota

Michelle F Waldman

Provided herein are methods of treating and/or managing cancers, which comprise administering to a patient Compound A, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in combination with daratumumab. Additionally, provided herein are methods of treating and/or managing cancers, which comprise administering to a patient Compound A, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in combination with daratumumab and dexamethasone.

Combination therapy for the treatment of cancer

Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation or IDH2 mutation.

Methods of treatment of malignancies

Provided herein are cereblon isoforms and methods of their use as biomarkers for treating a disease, disorder, or condition with a treatment compound, e.g., thalidomide, lenalidomide, pomalidomide, 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)-piperidine-2,6-dione, or (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione.

Cereblon isoforms and their use as biomarkers for therapeutic treatment

Growing community of inventors

Madison, NJ, United States of America

Michael D Amatangelo